Login Register Cart 0
Generic placeholder image

Current Vascular Pharmacology

Editor-in-Chief

ISSN (Print): 1570-1611
ISSN (Online): 1875-6212

Back
Journal Home About Journal Editorial Board Journal Insight Current Issue Volumes/Issues
Subscribe
Review Article

Beta-blockers in Hypertensive Left Ventricular Hypertrophy and Atrial Fibrillation Prevention

Author(s): Goran Koraćević, Sladjana Mićić, Milovan Stojanović*, Marija Zdravkovic, Dragan Simić, Tomislav Kostić, Vesna Atanasković and Ružica Janković-Tomašević

Volume 22, Issue 1, 2024

Published on: 27 November, 2023

Page: [19 - 27] Pages: 9

DOI: 10.2174/0115701611264647231110101700

Price: $65

Abstract

Background: Hypertensive left ventricular hypertrophy (HTN LVH) is a key risk factor for atrial fibrillation (AF).

Objective: To evaluate the possible role of beta-blockers (BBs) in addition to a renin-angiotensinaldosterone system (RAAS) blocker in AF prevention in patients with HTN LVH.

Methods: We performed a PubMed, Elsevier, SAGE, Oxford, and Google Scholar search with the search items ‘beta blocker hypertension left ventricular hypertrophy patient’ from 2013-2023. In the end, a ‘snowball search’, based on the references of relevant papers as well as from papers that cited them was performed.

Results: HTN LVH is a risk factor for AF. In turn, AF substantially complicates HTN LVH and contributes to the genesis of heart failure (HF) with preserved ejection fraction (HFpEF). The prognosis of HFpEF is comparable with that of HF with reduced EF (HFrEF), and, regardless of the type, HF is associated with five-year mortality of 50-75%. The antiarrhythmic properties of BBs are wellrecognized, and BBs as a class of drugs are - in general - recommended to decrease the incidence of AF in HTN.

Conclusion: BBs are recommended (as a class) for AF prevention in several contemporary guidelines for HTN. LVH regression in HTN - used as a single criterion for the choice of antihypertensive medication - does not capture this protective effect. Consequently, it is worth studying how meaningful this antiarrhythmic action (to prevent AF) of BBs is in patients with HTN LVH in addition to a RAAS blocker.

« Previous Next »
Graphical Abstract

[1]
Mancusi C, Lembo M, Manzi MV, Basile C, Fucile I, Morisco C. From structural to functional hypertension mediated target organ damage—a long way to heart failure with preserved ejection fraction. J Clin Med 2022; 11(18): 5377.
[http://dx.doi.org/10.3390/jcm11185377] [PMID: 36143024]
[2]
Wang T, Zhong H, Lian G, et al. Low-grade albuminuria is associated with left ventricular hypertrophy and diastolic dysfunction in patients with hypertension. Kidney Blood Press Res 2019; 44(4): 590-603.
[http://dx.doi.org/10.1159/000500782] [PMID: 31387099]
[3]
Kim Y, Cho JS, Cho W, et al. Retinopathy and left ventricular hypertrophy in patients with chronic kidney disease: interrelationship and impact on clinical outcomes. Int J Cardiol 2017; 249: 372-6.
[http://dx.doi.org/10.1016/j.ijcard.2017.06.123] [PMID: 29121742]
[4]
Ovchinnikov A, Belyavskiy E, Potekhina A, Ageev F. Asymptomatic left ventricular hypertrophy is a potent risk factor for the development of hfpef but not hfref: Results of a retrospective cohort study. J Clin Med 2022; 11(13): 3885.
[http://dx.doi.org/10.3390/jcm11133885] [PMID: 35807166]
[5]
Tackling G, Borhade MB. Hypertensive heart disease. StatPearls. Treasure Island, FL: StatPearls Publishing 2022. Available from: https://www.ncbi.nlm.nih.gov/books/NBK539800/ Updated 2022 Jun 27 Jan.
[6]
Al Alwany AA. Arrhythmia related to hypertensive left ventricular hypertrophy in Iraqi patients: Frequency and outcome. J Med Life 2022; 15(9): 1115-8.
[http://dx.doi.org/10.25122/jml-2022-0214] [PMID: 36415521]
[7]
Koracevic G, Perisic Z, Stanojkovic M, et al. A discrepancy: Calcium channel blockers are effective for the treatment of hypertensive left ventricular hypertrophy but not as effective for prevention of heart failure. Med Princ Pract 2022; 31(5): 454-62.
[http://dx.doi.org/10.1159/000526792] [PMID: 36044874]
[8]
Zhang H, Hu L, Wei X. Prognostic value of left ventricular hypertrophy in hypertensive patients: A meta-analysis of electrocardiographic studies. J Clin Hypertens 2020; 22(2): 254-60.
[http://dx.doi.org/10.1111/jch.13795] [PMID: 31955500]
[9]
Bang CN, Greve AM, Køber L, et al. Incident atrial fibrillation and heart failure in treated hypertensive patients with left ventricular hypertrophy. The life study. Exploration of Medicine 2022; 3: 139-48.
[http://dx.doi.org/10.37349/emed.2022.00080]
[10]
Noori AA, Barzani MA. Predictors of impaired left ventricular global longitudinal strain in patients with essential hypertension and preserved ejection fraction. Open Cardiovasc Med J 2022; 16(1): e187419242212020.
[http://dx.doi.org/10.2174/18741924-v16-e221202-2022-8]
[11]
Nadar SK, Lip GYH. The heart in hypertension. J Hum Hypertens 2021; 35(5): 383-6.
[http://dx.doi.org/10.1038/s41371-020-00427-x] [PMID: 33046827]
[12]
Erküner Ö, Dudink EAMP, Nieuwlaat R, et al. Effect of systemic hypertension with versus without left ventricular hypertrophy on the progression of atrial fibrillation (from the euro heart survey). Am J Cardiol 2018; 122(4): 578-83.
[http://dx.doi.org/10.1016/j.amjcard.2018.04.053] [PMID: 29958714]
[13]
Okin PM, Wachtell K, Kjeldsen SE, et al. Incidence of atrial fibrillation in relation to changing heart rate over time in hypertensive patients: The LIFE study. Circ Arrhythm Electrophysiol 2008; 1(5): 337-43.
[http://dx.doi.org/10.1161/CIRCEP.108.795351] [PMID: 19808428]
[14]
Lip GYH, Coca A, Kahan T, et al. Hypertension and cardiac arrhythmias: executive summary of a consensus document from the european heart rhythm association (ehra) and esc council on hypertension, endorsed by the heart rhythm society (hrs), asia-pacific heart rhythm society (aphrs) and sociedad latinoamericana de estimulación cardíaca y electrofisiología (SOLEACE). Eur Heart J Cardiovasc Pharmacother 2017; 3(4): 235-50.
[http://dx.doi.org/10.1093/ehjcvp/pvx019] [PMID: 28541499]
[15]
Koraćević G, Stojković M, Stojanović M, et al. Less known but clinically relevant comorbidities of atrial fibrillation: A narrative review. Curr Vasc Pharmacol 2022; 20(5): 429-38.
[http://dx.doi.org/10.2174/1570161120666220819095215] [PMID: 35986547]
[16]
Kanazawa S, Kaneko H, Yano Y, et al. Sex differences in the association between hypertension and incident atrial fibrillation. J Am Heart Assoc 2023; 12(5): e026240.
[http://dx.doi.org/10.1161/JAHA.122.026240] [PMID: 36802850]
[17]
Li H, Song X, Liang Y, et al. Global, regional, and national burden of disease study of atrial fibrillation/flutter, 1990–2019: Results from a global burden of disease study, 2019. BMC Public Health 2022; 22(1): 2015.
[http://dx.doi.org/10.1186/s12889-022-14403-2] [PMID: 36329400]
[18]
Koracevic G, Mićić S, Stojanovic M, et al. In many patients with hypertensive left ventricular hypertrophy, a beta-blocker is needed because of the prevalent myocardial ischemia. Curr Vasc Pharmacol 2023. Epub ahead of print
[http://dx.doi.org/10.2174/1570161121666230201141215] [PMID: 36722475]
[19]
Dabrowski R, Borowiec A, Smolis-Bak E, et al. Effect of combined spironolactone-β-blocker ± enalapril treatment on occurrence of symptomatic atrial fibrillation episodes in patients with a history of paroxysmal atrial fibrillation (SPIR-AF study). Am J Cardiol 2010; 106(11): 1609-14.
[http://dx.doi.org/10.1016/j.amjcard.2010.07.037] [PMID: 21094362]
[20]
Okin PM, Bang CN, Wachtell K, et al. Relationship of sudden cardiac death to new-onset atrial fibrillation in hypertensive patients with left ventricular hypertrophy. Circ Arrhythm Electrophysiol 2013; 6(2): 243-51.
[http://dx.doi.org/10.1161/CIRCEP.112.977777] [PMID: 23403268]
[21]
Lee SR, Park CS, Choi EK, et al. Hypertension Burden and the Risk of New-Onset Atrial Fibrillation. Hypertension 2021; 77(3): 919-28.
[http://dx.doi.org/10.1161/HYPERTENSIONAHA.120.16659] [PMID: 33486985]
[22]
Umemura S, Arima H, Arima S, et al. The Japanese society of hypertension guidelines for the management of hypertension (jsh 2019). Hypertens Res 2019; 42(9): 1235-481.
[http://dx.doi.org/10.1038/s41440-019-0284-9] [PMID: 31375757]
[23]
Shenasa M, Shenasa H. Hypertension, left ventricular hypertrophy, and sudden cardiac death. Int J Cardiol 2017; 237: 60-3.
[http://dx.doi.org/10.1016/j.ijcard.2017.03.002] [PMID: 28285801]
[24]
Chen C, Liu L, Yu Y, et al. Association of systolic blood pressure with atrial fibrillation among treated hypertensive patients. Ann Palliat Med 2020; 9(4): 1752-63.
[http://dx.doi.org/10.21037/apm-19-649] [PMID: 32527128]
[25]
De Vos CB, Breithardt G, Camm AJ, et al. Progression of atrial fibrillation in the REgistry on Cardiac rhythm disORDers assessing the control of Atrial Fibrillation cohort: Clinical correlates and the effect of rhythm-control therapy. Am Heart J 2012; 163(5): 887-93.
[http://dx.doi.org/10.1016/j.ahj.2012.02.015] [PMID: 22607868]
[26]
Lip GYH, Nieuwlaat R, Pisters R, Lane DA, Crijns HJGM. Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach: the euro heart survey on atrial fibrillation. Chest 2010; 137(2): 263-72.
[http://dx.doi.org/10.1378/chest.09-1584] [PMID: 19762550]
[27]
Olesen JB, Lip GYH, Hansen ML, et al. Validation of risk stratification schemes for predicting stroke and thromboembolism in patients with atrial fibrillation: nationwide cohort study. BMJ 2011; 342(jan31 1): d124.
[http://dx.doi.org/10.1136/bmj.d124] [PMID: 21282258]
[28]
Patel N, O’Neal WT, Whalen SP, Soliman EZ. Electrocardiographic left ventricular hypertrophy predicts atrial fibrillation independent of left ventricular mass. Ann Noninvasive Electrocardiol 2017; 22(3): e12419.
[http://dx.doi.org/10.1111/anec.12419] [PMID: 28019050]
[29]
Stewart MH, Lavie CJ, Shah S, et al. Prognostic implications of left ventricular hypertrophy. Prog Cardiovasc Dis 2018; 61(5-6): 446-55.
[http://dx.doi.org/10.1016/j.pcad.2018.11.002] [PMID: 30408469]
[30]
Chrispin J, Jain A, Soliman EZ, et al. Association of electrocardiographic and imaging surrogates of left ventricular hypertrophy with incident atrial fibrillation: MESA (Multi-Ethnic Study of Atherosclerosis). J Am Coll Cardiol 2014; 63(19): 2007-13.
[http://dx.doi.org/10.1016/j.jacc.2014.01.066] [PMID: 24657688]
[31]
Padfield GJ, Steinberg C, Swampillai J, et al. Progression of paroxysmal to persistent atrial fibrillation: 10-year follow-up in the canadian registry of atrial fibrillation. Heart Rhythm 2017; 14(6): 801-7.
[http://dx.doi.org/10.1016/j.hrthm.2017.01.038] [PMID: 28232263]
[32]
Lip GYH, Coca A, Kahan T, et al. Hypertension and cardiac arrhythmias: A consensus document from the European Heart Rhythm Association (EHRA) and ESC Council on Hypertension, endorsed by the Heart Rhythm Society (HRS), Asia-Pacific Heart Rhythm Society (APHRS) and Sociedad Latinoamericana de Estimulación Cardíaca y Electrofisiología (SOLEACE). Europace 2017; 19(6): 891-911.
[http://dx.doi.org/10.1093/europace/eux091] [PMID: 28881872]
[33]
Marazzato J, Blasi F, Golino M, Verdecchia P, Angeli F, De Ponti R. Hypertension and Arrhythmias: A clinical overview of the pathophysiology-driven management of cardiac arrhythmias in hypertensive patients. J Cardiovasc Dev Dis 2022; 9(4): 110.
[http://dx.doi.org/10.3390/jcdd9040110] [PMID: 35448086]
[34]
Koracevic G, Mićić S, Stojanović M, et al. High likelihood for atrial fibrillation in Cushing’s syndrome. Eur Rev Med Pharmacol Sci 2020; 24(3): 1391-7.
[http://dx.doi.org/10.26355/eurrev_202002_20196] [PMID: 32096188]
[35]
Seko Y, Kato T, Haruna T, et al. Association between atrial fibrillation, atrial enlargement, and left ventricular geometric remodeling. Sci Rep 2018; 8(1): 6366.
[http://dx.doi.org/10.1038/s41598-018-24875-1] [PMID: 29686287]
[36]
Verdecchia P, Reboldi G, Gattobigio R, et al. Atrial fibrillation in hypertension: Predictors and outcome. Hypertension 2003; 41(2): 218-23.
[http://dx.doi.org/10.1161/01.HYP.0000052830.02773.E4] [PMID: 12574085]
[37]
Proietti M, Marra AM, Tassone EJ, et al. Frequency of left ventricular hypertrophy in non-valvular atrial fibrillation. Am J Cardiol 2015; 116(6): 877-82.
[http://dx.doi.org/10.1016/j.amjcard.2015.05.060] [PMID: 26183791]
[38]
Choi J, Lee SR, Choi EK, et al. Accumulated hypertension burden on atrial fibrillation risk in diabetes mellitus: A nationwide population study. Cardiovasc Diabetol 2023; 22(1): 12.
[http://dx.doi.org/10.1186/s12933-023-01736-4] [PMID: 36658574]
[39]
Huang PH, Huang CC, Lin SJ, Chen JW. Prediction of atrial fibrillation in patients with hypertension: A comprehensive comparison of office and ambulatory blood pressure measurements. J Clin Hypertens 2022; 24(7): 838-47.
[http://dx.doi.org/10.1111/jch.14524] [PMID: 35695288]
[40]
Varvarousis D, Kallistratos M, Poulimenos L, et al. Cardiac arrhythmias in arterial hypertension. J Clin Hypertens 2020; 22(8): 1371-8.
[http://dx.doi.org/10.1111/jch.13989] [PMID: 32772484]
[41]
Qiu D, Peng L, Ghista DN, Wong KKL. Left atrial remodeling mechanisms associated with atrial fibrillation. Cardiovasc Eng Technol 2021; 12(3): 361-72.
[http://dx.doi.org/10.1007/s13239-021-00527-w] [PMID: 33650086]
[42]
Ihara K, Sasano T. Role of inflammation in the pathogenesis of atrial fibrillation. Front Physiol 2022; 13: 862164.
[http://dx.doi.org/10.3389/fphys.2022.862164] [PMID: 35492601]
[43]
Messerli FH, Ventura HO, Elizardi DJ, Dunn FG, Frohlich ED. Hypertension and sudden death. Am J Med 1984; 77(1): 18-22.
[http://dx.doi.org/10.1016/0002-9343(84)90430-3] [PMID: 6234799]
[44]
Kannel WB, Schatzkin A. Sudden death: Lessons from subsets in population studies. J Am Coll Cardiol 1985; 5(6) (Suppl.): 141B-9B.
[http://dx.doi.org/10.1016/S0735-1097(85)80545-3] [PMID: 3889106]
[45]
McLenachan JM, Henderson E, Morris KI, Dargie HJ. Ventricular arrhythmias in patients with hypertensive left ventricular hypertrophy. N Engl J Med 1987; 317(13): 787-92.
[http://dx.doi.org/10.1056/NEJM198709243171302] [PMID: 2957590]
[46]
Levy D, Anderson KM, Savage DD, Balkus SA, Kannel WB, Castelli WP. Risk of ventricular arrhythmias in left ventricular hypertrophy: the Framingham Heart Study. Am J Cardiol 1987; 60: 560e565.
[http://dx.doi.org/10.1016/0002-9149(87)90305-5]
[47]
Ghali JK, Kadakia S, Cooper RS, Liao Y. Impact of left ventricular hypertrophy on ventricular arrhythmias in the absence of coronary artery disease. J Am Coll Cardiol 1991; 17(6): 1277-82.
[http://dx.doi.org/10.1016/S0735-1097(10)80135-4] [PMID: 1826691]
[48]
Schmieder RE, Messerli FH. Determinants of ventricular ectopy in hypertensive cardiac hypertrophy. Am Heart J 1992; 123(1): 89-95.
[http://dx.doi.org/10.1016/0002-8703(92)90751-G] [PMID: 1530898]
[49]
Vester EG, Kuhls S, Ochiulet-Vester J, Vogt M, Strauer BE. Electrophysiological and therapeutic implications of cardiac arrhythmias in hypertension. Eur Heart J 1992; 13 (Suppl. D): 70-81.
[http://dx.doi.org/10.1093/eurheartj/13.suppl_D.70] [PMID: 1396864]
[50]
Wolk R. Arrhythmogenic mechanisms in left ventricular hypertrophy. Europace 2000; 2(3): 216-23.
[http://dx.doi.org/10.1053/eupc.2000.0110] [PMID: 11227591]
[51]
Greenberg MD, Papademetriou V, Narayan P, Kokkinos P. Nonsustained Ventricular Tachycardia as a Predictor of Cardiovascular Events in Black Men With Hypertensive Left Ventricular Hypertrophy. J Clin Hypertens 2000; 2(1): 14-9.
[PMID: 11416620]
[52]
Sundström J, Lind L, Ärnlöv J, Zethelius B, Andrén B, Lithell HO. Echocardiographic and electrocardiographic diagnoses of left ventricular hypertrophy predict mortality independently of each other in a population of elderly men. Circulation 2001; 103(19): 2346-51.
[http://dx.doi.org/10.1161/01.CIR.103.19.2346] [PMID: 11352882]
[53]
Chatterjee S, Bavishi C, Sardar P, et al. Meta-analysis of left ventricular hypertrophy and sustained arrhythmias. Am J Cardiol 2014; 114(7): 1049-52.
[http://dx.doi.org/10.1016/j.amjcard.2014.07.015] [PMID: 25118122]
[54]
Rautaharju PM, Soliman EZ. Electrocardiographic left ventricular hypertrophy and the risk of adverse cardiovascular events: A critical appraisal. J Electrocardiol 2014; 47(5): 649-54.
[http://dx.doi.org/10.1016/j.jelectrocard.2014.06.002] [PMID: 25012077]
[55]
Narayanan K, Reinier K, Teodorescu C, et al. Electrocardiographic versus echocardiographic left ventricular hypertrophy and sudden cardiac arrest in the community. Heart Rhythm 2014; 11(6): 1040-6.
[http://dx.doi.org/10.1016/j.hrthm.2014.03.023] [PMID: 24657425]
[56]
Narayanan K, Reinier K, Teodorescu C, et al. Left ventricular diameter and risk stratification for sudden cardiac death. J Am Heart Assoc 2014; 3(5): e001193.
[http://dx.doi.org/10.1161/JAHA.114.001193] [PMID: 25227407]
[57]
Narayanan K, Chugh SS. The 12-lead electrocardiogram and risk of sudden death: current utility and future prospects. Europace 2015; 17 Suppl 2(Suppl 2): ii7-ii13.
[http://dx.doi.org/10.1093/europace/euv121]
[58]
Aro AL, Chugh SS. Clinical Diagnosis of Electrical Versus Anatomic Left Ventricular Hypertrophy: Prognostic and Therapeutic Implications. Circ Arrhythm Electrophysiol 2016; 9(4): e003629.
[http://dx.doi.org/10.1161/CIRCEP.115.003629] [PMID: 27009417]
[59]
Chugh SS. Einthoven and electrical risk: Value of the electrocardiogram to predict sudden cardiac death. J Cardiovasc Electrophysiol 2018; 29(1): 61-3.
[http://dx.doi.org/10.1111/jce.13360] [PMID: 28988446]
[60]
Verdecchia P, Angeli F, Cavallini C, et al. Sudden cardiac death in hypertensive patients. Hypertension 2019; 73(5): 1071-8.
[http://dx.doi.org/10.1161/HYPERTENSIONAHA.119.12684] [PMID: 30827144]
[61]
Cunningham KS, Spears DA, Care M. Evaluation of cardiac hypertrophy in the setting of sudden cardiac death. Forensic Sci Res 2019; 4(3): 223-40.
[http://dx.doi.org/10.1080/20961790.2019.1633761] [PMID: 31489388]
[62]
Cuspidi C, Sala C, Negri F, Mancia G, Morganti A. Prevalence of left-ventricular hypertrophy in hypertension: an updated review of echocardiographic studies. J Hum Hypertens 2012; 26(6): 343-9.
[http://dx.doi.org/10.1038/jhh.2011.104] [PMID: 22113443]
[63]
Li SN, Wang L, Dong JZ, et al. Electrocardiographic left ventricular hypertrophy predicts recurrence of atrial arrhythmias after catheter ablation of paroxysmal atrial fibrillation. Clin Cardiol 2018; 41(6): 797-802.
[http://dx.doi.org/10.1002/clc.22957] [PMID: 29604089]
[64]
Wang C, Du Z, Ye N, Liu S, Geng D, Sun Y. Prevalence and prognosis of atrial fibrillation in a hypertensive population: A prospective cohort study. J Clin Hypertens 2023; 25(4): 335-42.
[http://dx.doi.org/10.1111/jch.14643] [PMID: 36866435]
[65]
Liao LZ, Wen XY, Zhang SZ, Li WD, Zhuang XD. Hypertension and Atrial Fibrillation: A Study on Epidemiology and Mendelian Randomization Causality. Front Cardiovasc Med 2021; 8(8): 644405.
[http://dx.doi.org/10.3389/fcvm.2021.644405] [PMID: 33834045]
[66]
Xiang H, Xue Y, Chen Z, et al. The association between left ventricular hypertrophy and the occurrence and prognosis of atrial fibrillation: A meta-analysis. Front Cardiovasc Med 2021; 8: 639993.
[http://dx.doi.org/10.3389/fcvm.2021.639993] [PMID: 34395549]
[67]
Hindricks G, Potpara T, Dagres N, et al. 2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS). Eur Heart J 2021; 42(5): 373-498.
[http://dx.doi.org/10.1093/eurheartj/ehaa612] [PMID: 32860505]
[68]
Sayin BY, Oto A. Left Ventricular Hypertrophy: Etiology-Based Therapeutic Options. Cardiol Ther 2022; 11(2): 203-30.
[http://dx.doi.org/10.1007/s40119-022-00260-y] [PMID: 35353354]
[69]
Xu W, Yang Y, Zhu J, et al. Impact of renin–angiotensin–aldosterone-system inhibitor drugs on mortality in patients with atrial fibrillation and hypertension. BMC Cardiovasc Disord 2022; 22(1): 141.
[http://dx.doi.org/10.1186/s12872-022-02580-2] [PMID: 35365067]
[70]
Yu Z, Zhang D, Ji Q, Yi F. Inhibition of the renin-angiotensin-aldosterone system prevents and cures atrial fibrillation. Medicine 2021; 100(18): e25559.
[http://dx.doi.org/10.1097/MD.0000000000025559] [PMID: 33950930]
[71]
Matei LL, Siliste C, Vinereanu D. Modifiable risk factors and atrial fibrillation: the quest for a personalized approach. Maedica 2021; 16(1): 88-96.
[http://dx.doi.org/10.26574/maedica.2020.16.1.88] [PMID: 34221161]
[72]
Holmqvist F, Kim S, Steinberg BA, et al. Heart rate is associated with progression of atrial fibrillation, independent of rhythm. Heart 2015; 101(11): 894-9.
[http://dx.doi.org/10.1136/heartjnl-2014-307043] [PMID: 25732748]
[73]
Puig E, Clará A, Pérez S, et al. Resting heart rate, cardiovascular events, and all-cause mortality: the REGICOR study. Eur J Prev Cardiol 2022; 5(29(5)): e200-2.
[http://dx.doi.org/10.1093/eurjpc/zwab148]
[74]
Mancia G, Fagard R, Narkiewicz K, et al. 2013 ESH/ESC guidelines for the management of arterial hypertension. Eur Heart J 2013; 34(28): 2159-219.
[http://dx.doi.org/10.1093/eurheartj/eht151] [PMID: 23771844]
[75]
Williams B, Mancia G, Spiering W, et al. 2018 ESC/ESH guidelines for the management of arterial hypertension. Eur Heart J 2018; 39(33): 3021-104.
[http://dx.doi.org/10.1093/eurheartj/ehy339] [PMID: 30165516]
[76]
Tay JC, Sule AA, Chew EK, et al. Ministry of health clinical practice guidelines: Hypertension. Singapore Med J 2018; 59(1): 17-27.
[http://dx.doi.org/10.11622/smedj.2018007] [PMID: 29376186]
[77]
Hua Q, Fan L, Li J. 2019 Chinese guideline for the management of hypertension in the elderly. J Geriatr Cardiol 2019; 16(2): 67-99.
[http://dx.doi.org/10.11909/j.issn.1671-5411.2019.02.001] [PMID: 30923539]
[78]
Koracevic G, Micic S, Stojanovic M, et al. Compelling indications should be listed for individual beta-blockers (due to diversity), not for the whole class. Curr Vasc Pharmacol 2021; 19(4): 343-6.
[http://dx.doi.org/10.2174/1570161118666200518113833] [PMID: 32418526]
[79]
Huang TC, Lee PT, Huang MS, Chiu PH, Su PF, Liu PY. The beneficial effects of beta blockers on the long-term prognosis of patients with premature atrial complexes. Front Cardiovasc Med 2022; 9: 806743.
[http://dx.doi.org/10.3389/fcvm.2022.806743] [PMID: 35252388]
[80]
Kim D, Yang PS, Joung B. Optimal rhythm control strategy in patients with atrial fibrillation. Korean Circ J 2022; 52(7): 496-512.
[http://dx.doi.org/10.4070/kcj.2022.0078] [PMID: 35790494]
[81]
Dézsi CA, Szentes V. The real role of β-blockers in daily cardiovascular therapy. Am J Cardiovasc Drugs 2017; 17(5): 361-73.
[http://dx.doi.org/10.1007/s40256-017-0221-8] [PMID: 28357786]
[82]
Grandi E, Ripplinger CM. Antiarrhythmic mechanisms of beta blocker therapy. Pharmacol Res 2019; 146: 104274.
[http://dx.doi.org/10.1016/j.phrs.2019.104274] [PMID: 31100336]
[83]
Ardaya R, Pratita J, Juliafina NN, Rahman FHF, Leonardo K. Amiodarone versus beta-blockers for the prevention of postoperative atrial fibrillation after cardiac surgery: An updated systematic review and meta-analysis of randomised controlled trials. F1000 Res 2022; 11: 569. [version 1; peer review: awaiting peer review].
[http://dx.doi.org/10.12688/f1000research.121598.1]
[84]
Eskerud I, Gerdts E, Larsen TH, Lønnebakken MT. Left ventricular hypertrophy contributes to myocardial ischemia in non-obstructive coronary artery disease (the MicroCAD study). Int J Cardiol 2019; 286: 1-6.
[http://dx.doi.org/10.1016/j.ijcard.2019.03.059] [PMID: 30952529]
[85]
Afrăsânie I, Matei IT, Leancă SA, et al. Ischemia with nonobstructive coronary artery disease and atrial cardiomyopathy—two sides of the same story? Life 2023; 13(2): 443.
[http://dx.doi.org/10.3390/life13020443] [PMID: 36836800]
[86]
Sharma YP, Batta A, Makkar K, et al. Angiographic profile and outcomes in persistent non-valvular atrial fibrillation: A study from tertiary care center in north India. Indian Heart J 2022; 74(1): 7-12.
[http://dx.doi.org/10.1016/j.ihj.2021.12.010] [PMID: 34958796]
[87]
Pugliese NR, Pellicori P, Filidei F, et al. Inflammatory pathways in heart failure with preserved left ventricular ejection fraction: implications for future interventions. Cardiovasc Res 2023; 118(18): 3536-55.
[http://dx.doi.org/10.1093/cvr/cvac133] [PMID: 36004819]
[88]
Petre I, Diaconeasa A, Onciul S, et al. Atrial fibrillation influence on left ventricular function in hypertensive patients with preserved ejection fraction. J Hypertens 2021; 39 (Suppl. 1): e97-8.
[http://dx.doi.org/10.1097/01.hjh.0000745376.44344.37]
[89]
Bertacchini F, Agabiti Rosei C, Buso G, et al. Subclinical HMOD in hypertension: Left ventricular diastolic dysfunction. High Blood Press Cardiovasc Prev 2022; 29(6): 585-93.
[http://dx.doi.org/10.1007/s40292-022-00548-z] [PMID: 36352335]
[90]
Bisbal F, Baranchuk A, Braunwald E, Bayés de Luna A, Bayés-Genís A. Atrial failure as a clinical entity. J Am Coll Cardiol 2020; 75(2): 222-32.
[http://dx.doi.org/10.1016/j.jacc.2019.11.013] [PMID: 31948652]
[91]
Wachtell K, Okin PM, Olsen MH, et al. Regression of electrocardiographic left ventricular hypertrophy during antihypertensive therapy and reduction in sudden cardiac death: The LIFE study. Circulation 2007; 116(7): 700-5.
[http://dx.doi.org/10.1161/CIRCULATIONAHA.106.666594] [PMID: 17664372]
[92]
Okin PM, Hille DA, Kjeldsen SE, Julius S, Dahlöf B, Devereux RB. Sudden cardiac death in relation to changing heart rate during treatment of hypertension: The LIFE study. J Am Coll Cardiol 2010; 55: A140-E311.
[http://dx.doi.org/10.1016/S0735-1097(10)61312-5]
[93]
Yang Y, Guo S, Huang Z, et al. Decreased mortality with beta-blocker therapy in HFpEF patients associated with atrial fibrillation. Cardiol Res Pract 2020; 2020: 1-7.
[http://dx.doi.org/10.1155/2020/3059864] [PMID: 32454997]
[94]
McDonagh TA, Metra M, Adamo M, et al. 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J 2021; 42(36): 3599-726.
[http://dx.doi.org/10.1093/eurheartj/ehab368] [PMID: 34447992]
[95]
Jasinska-Piadlo A, Campbell P. Management of patients with heart failure and preserved ejection fraction. Heart 2023; 109(11): 874-83.
[http://dx.doi.org/10.1136/heartjnl-2022-321097] [PMID: 36948571]
[96]
Fauchier L, Bisson A, Bodin A. Heart failure with preserved ejection fraction and atrial fibrillation: Recent advances and open questions. BMC Med 2023; 21(1): 54.
[http://dx.doi.org/10.1186/s12916-023-02764-3] [PMID: 36782248]
[97]
Zhang J, Xu M, Chen T, Zhou Y. Correlation between liver stiffness and diastolic function, left ventricular hypertrophy, and right cardiac function in patients with ejection fraction preserved heart failure. Front Cardiovasc Med 2021; 8: 748173.
[http://dx.doi.org/10.3389/fcvm.2021.748173] [PMID: 34901210]
[98]
Schulz A, Schuster A. Visualizing diastolic failure: Non-invasive imaging-biomarkers in patients with heart failure with preserved ejection fraction. EBioMedicine 2022; 86: 104369.
[http://dx.doi.org/10.1016/j.ebiom.2022.104369] [PMID: 36423377]
[99]
Rismiati H, Lee HY. Hypertensive heart failure in Asia. Pulse 2021; 9(3-4): 47-56.
[http://dx.doi.org/10.1159/000518661] [PMID: 35083170]
[100]
Kuo JY, Chang SH, Sung KT, et al. Left ventricular dysfunction in atrial fibrillation and heart failure risk. ESC Heart Fail 2020; 7(6): 3694-706.
[http://dx.doi.org/10.1002/ehf2.12920] [PMID: 32929859]
[101]
Packer M. Characterization, pathogenesis, and clinical implications of inflammation-related atrial myopathy as an important cause of atrial fibrillation. J Am Heart Assoc 2020; 9(7): e015343.
[http://dx.doi.org/10.1161/JAHA.119.015343] [PMID: 32242478]
[102]
Prasad R, Banga S, Salazar AM, et al. Correlation between atrial fibrillation and heart failure with preserved ejection fraction: A review. J Cardiol Clin Res 2022; 10(1): 1178.
[103]
Hao C, Luo J, Liu B, et al. Prognostic significance of new-onset atrial fibrillation in heart failure with preserved, mid-range, and reduced ejection fraction following acute myocardial infarction: Data from the NOAFCAMI-SH registry. Clin Interv Aging 2022; 17: 479-93.
[http://dx.doi.org/10.2147/CIA.S358349] [PMID: 35444413]
[104]
Wołowiec Ł, Grześk G, Osiak J, et al. Beta-blockers in cardiac arrhythmias–Clinical pharmacologist’s point of view. Front Pharmacol 2023; 13; (3): 1043714.
[http://dx.doi.org/10.3389/fphar.2022.1043714] [PMID: 36699057]
[105]
Brugada J, Katritsis DG, Arbelo E, et al. 2019 ESC guidelines for the management of patients with supraventricular tachycardiathe task force for the management of patients with supraventricular tachycardia of the european society of cardiology (ESC). Eur Heart J 2020; 41(5): 655-720.
[http://dx.doi.org/10.1093/eurheartj/ehz467] [PMID: 31504425]
[106]
Zeppenfeld K, Tfelt-Hansen J, de Riva M, et al. 2022 ESC guidelines for the management of patients with ventricular arrhythmias and the prevention of sudden cardiac death. Eur Heart J 2022; 43(40): 3997-4126.
[http://dx.doi.org/10.1093/eurheartj/ehac262] [PMID: 36017572]
[107]
Habel N, du Fay de Lavallaz J, Infeld M, et al. Lower heart rates and beta-blockers are associated with new-onset atrial fibrillation. International Journal of Cardiology Cardiovascular Risk and Prevention 2023; 17: 200182.
[http://dx.doi.org/10.1016/j.ijcrp.2023.200182] [PMID: 36911071]
[108]
Marott SCW, Nielsen SF, Benn M, Nordestgaard BG. Antihypertensive treatment and risk of atrial fibrillation: A nationwide study. Eur Heart J 2014; 35(18): 1205-14.
[http://dx.doi.org/10.1093/eurheartj/eht507] [PMID: 24347316]
[109]
Sardana M, Syed AA, Hashmath Z, et al. Beta-blocker use is associated with impaired left atrial function in hypertension. J Am Heart Assoc 2017; 6(2): e005163.
[http://dx.doi.org/10.1161/JAHA.116.005163] [PMID: 28159822]
[110]
Maddox TM, Januzzi JL Jr, Allen LA, et al. 2021 Update to the 2017 acc expert consensus decision pathway for optimization of heart failure treatment: Answers to 10 pivotal issues about heart failure with reduced ejection fraction. J Am Coll Cardiol 2021; 77(6): 772-810.
[http://dx.doi.org/10.1016/j.jacc.2020.11.022] [PMID: 33446410]
[111]
Chen JS, Pei Y, Li C, Li Y, Wang Q, Yu J. Comparative efficacy of different types of antihypertensive drugs in reversing left ventricular hypertrophy as determined with echocardiography in hypertensive patients: A network meta-analysis of randomized controlled trials. J Clin Hypertens 2020; 22(12): 2175-83.
[http://dx.doi.org/10.1111/jch.14047] [PMID: 33190366]
[112]
Ahmed SN, Jhaj R, Sadasivam B, Joshi R. Regression of the left ventricular hypertrophy in patients with essential hypertension on standard drug therapy. Discoveries 2020; 8(3): e115.
[http://dx.doi.org/10.15190/d.2020.12] [PMID: 33102689]
[113]
Ma H, Jiang H, Feng J, Gan Y. Angiotensin receptor blocker and calcium channel blocker preventing atrial fibrillation recurrence in patients with hypertension and atrial fibrillation: A meta-analysis. Cardiovasc Ther 2021; 2021: 1-8.
[http://dx.doi.org/10.1155/2021/6628469] [PMID: 34104205]
[114]
Cuspidi C, Negri F, Zanchetti A. Angiotensin II receptor blockers and cardiovascular protection: Focus on left ventricular hypertrophy regression and atrial fibrillation prevention. Vasc Health Risk Manag 2008; 4(1): 67-73.
[http://dx.doi.org/10.2147/vhrm.2008.04.01.67] [PMID: 18629360]
[115]
Fatima K, Asad D, Shaikh N, et al. A systematic review and meta-analysis on effectiveness of mineralocorticoid receptor antagonists in reducing the risk of atrial fibrillation. Am J Cardiol 2023; 199: 85-91.
[http://dx.doi.org/10.1016/j.amjcard.2023.04.038] [PMID: 37269781]
[116]
Mancia G, Kjeldsen SE, Kreutz R, Pathak A, Grassi G, Esler M. Individualized beta-blocker treatment for high blood pressure dictated by medical comorbidities: Indications beyond the 2018 european society of cardiology/european society of hypertension guidelines. Hypertension 2022; 79(6): 1153-66.
[http://dx.doi.org/10.1161/HYPERTENSIONAHA.122.19020] [PMID: 35378981]
[117]
Manolis AJ, Poulimenos LE, Kallistratos MS, Gavras I, Gavras H. Sympathetic overactivity in hypertension and cardiovascular disease. Curr Vasc Pharmacol 2014; 12(1): 4-15.
[http://dx.doi.org/10.2174/15701611113119990140] [PMID: 23905597]
[118]
Kallistratos MS, Poulimenos LE, Manolis AJ. Atrial fibrillation and arterial hypertension. Pharmacol Res 2018; 128: 322-6.
[http://dx.doi.org/10.1016/j.phrs.2017.10.007] [PMID: 29055746]

Rights & Permissions Print Cite
© 2024 Bentham Science Publishers | Privacy Policy